{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:58Z","timestamp":1792432018124,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T00:00:00Z","timestamp":1353974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00280-012-2035-3","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T12:58:31Z","timestamp":1353934711000},"page":"531-536","source":"Crossref","is-referenced-by-count":28,"title":["Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?"],"prefix":"10.1007","volume":"71","author":[{"given":"Peggy","family":"Gandia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"2035_CR1","doi-asserted-by":"crossref","unstructured":"Arellano C, Gandia P, Lafont T, Jongejan R, Chatelut E (2012) Determination of bound fraction of imatinib and N-desmethyl imatinib\u2014validation of an UPLC-MS\/MS assay and ultrafiltration method. J Chromatogr B Anal Technol Biomed Life Sci 907:94\u2013100","DOI":"10.1016\/j.jchromb.2012.09.007"},{"issue":"Suppl 4","key":"2035_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","volume":"20","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Dreyling M (2009) Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):105\u2013107","journal-title":"Ann Oncol"},{"key":"2035_CR3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"2035_CR4","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12:6073\u20136078","journal-title":"Clin Cancer Res"},{"key":"2035_CR5","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141\u20133147","journal-title":"J Clin Oncol"},{"key":"2035_CR6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"2035_CR7","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, De Giorgi U (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18:5780\u20135787","journal-title":"Clin Cancer Res"},{"key":"2035_CR8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.bbagen.2006.08.015","volume":"1760","author":"I Fitos","year":"2006","unstructured":"Fitos I, Visy J, Zsila F, Mady G, Simonyi M (2006) Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim Biophys Acta 1760:1704\u20131712","journal-title":"Biochim Biophys Acta"},{"key":"2035_CR9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","volume":"92","author":"C Gambacorti-Passerini","year":"2000","unstructured":"Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D\u2019Incalci M (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641\u20131650","journal-title":"J Natl Cancer Inst"},{"key":"2035_CR10","first-page":"625","volume":"9","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D\u2019Incalci M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625\u2013632","journal-title":"Clin Cancer Res"},{"key":"2035_CR11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","volume":"26","author":"J Gibbons","year":"2008","unstructured":"Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:570\u2013576","journal-title":"J Clin Oncol"},{"key":"2035_CR12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","volume":"33","author":"HP Gschwind","year":"2005","unstructured":"Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503\u20131512","journal-title":"Drug Metab Dispos"},{"key":"2035_CR13","doi-asserted-by":"crossref","unstructured":"Haouala A, Widmer N, Guidi M, Montemurro M, Leyvraz S, Buclin T, Eap CB, Decosterd L, Csajka C (2012) Prediction of free imatinib concentrations based on total plasma levels in gist patients. Br J Clin Pharmacol (in press)","DOI":"10.1111\/j.1365-2125.2012.04422.x"},{"key":"2035_CR14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2125.2004.02117.x","volume":"58","author":"O Kretz","year":"2004","unstructured":"Kretz O, Weiss HM, Schumacher MM, Gross G (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58:212\u2013216","journal-title":"Br J Clin Pharmacol"},{"key":"2035_CR15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0006-2952(03)00469-6","volume":"66","author":"J Larghero","year":"2003","unstructured":"Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E, Bastie JN, Degos L, Berthaud P, Marolleau JP, Calvo F, Chomienne C, Mahon FX, Rousselot P (2003) Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 66:1907\u20131913","journal-title":"Biochem Pharmacol"},{"key":"2035_CR16","first-page":"29","volume":"23","author":"C Guellec Le","year":"2009","unstructured":"Le Guellec C, Simon N, Hulot JS, Billaud EM, Marquet P (2009) Evidence-based therapeutic drug monitoring: a systematic assessment. La Lettre du Pharmacologue 23:29\u201333","journal-title":"La Lettre du Pharmacologue"},{"key":"2035_CR17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-010-1142-7","volume":"90","author":"P Mlejnek","year":"2011","unstructured":"Mlejnek P, Dolezel P, Faber E, Kosztyu P (2011) Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol 90:837\u2013842","journal-title":"Ann Hematol"},{"key":"2035_CR18","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"2035_CR19","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","volume":"23","author":"DA Reardon","year":"2005","unstructured":"Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359\u20139368","journal-title":"J Clin Oncol"},{"key":"2035_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","volume":"22","author":"S Shukla","year":"2008","unstructured":"Shukla S, Sauna ZE, Ambudkar SV (2008) Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 22:445\u2013447","journal-title":"Leukemia"},{"key":"2035_CR21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1592\/phco.24.16.1508.50958","volume":"24","author":"P Smith","year":"2004","unstructured":"Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ (2004) The influence of St. John\u2019s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24:1508\u20131514","journal-title":"Pharmacotherapy"},{"key":"2035_CR22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0b013e3182263ac4","volume":"33","author":"F Streit","year":"2011","unstructured":"Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P (2011) Use of total and unbound imatinib and metabolite LC-MS\/MS assay to understand individual responses in CML and GIST patients. Ther Drug Monit 33:632\u2013643","journal-title":"Ther Drug Monit"},{"key":"2035_CR23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697\u2013704","journal-title":"Blood"},{"key":"2035_CR24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T (2006) Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62:97\u2013112","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-2035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-2035-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-2035-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T20:47:15Z","timestamp":1745354835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-2035-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-2035-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,27]]}}}